| Literature DB >> 29547670 |
Annet Wijnen1,2, Sjoukje E Bouma2,3, Gesine H Seeber1, Lucas H V van der Woude3, Sjoerd K Bulstra2, Djordje Lazovic1, Martin Stevens2, Inge van den Akker-Scheek2.
Abstract
OBJECTIVE: To assess the therapeutic validity and effectiveness of physiotherapeutic exercise interventions following total hip arthroplasty (THA) for osteoarthritis. DATA SOURCES: The databases Embase, MEDLINE, Cochrane Library, CINAHL and AMED were searched from inception up to February 2017. ELIGIBILITY CRITERIA: Articles reporting results of randomized controlled trials in which physiotherapeutic exercise was compared with usual care or with a different type of physiotherapeutic exercise were included, with the applied interventions starting within six months after THA. Only articles written in English, German or Dutch were included. STUDY APPRAISAL: Therapeutic validity (using the CONTENT scale) and risk of bias (using both the PEDro scale and the Cochrane Collaboration's tool) were assessed by two researchers independently. Characteristics of the physiotherapeutic exercise interventions and results about joint and muscle function, functional performance and self-reported outcomes were extracted.Entities:
Mesh:
Year: 2018 PMID: 29547670 PMCID: PMC5856403 DOI: 10.1371/journal.pone.0194517
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The International Classification of Function, Disability and Health (ICF) model [13].
Fig 2Flow diagram of the article selection process.
THA: total hip arthroplasty; OA: osteoarthritis; RCT: randomized controlled trial.
Study characteristics of the included articles.
| Physiotherapeutic exercise intervention | Control intervention | Results | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author (year, location) | Study groups (n) | Age (years) | Women (n (%)) | Type | Setting | Duration (frequency | Intensity | Start and follow-up | Description | Frequency | Intensity | Joint & muscle function | Functional performance | Self-reported outcomes |
| Husby (2009, Norway) | IG: 12; CG: 12 | IG: 58 ± 5; CG: 56 ± 8 | 15 (63) | Strengthening (+ control intervention) | I; L (Y) | 4w (5x pw) | 4 series of 5RM | 1w; 5w | Usual care | 5x pw | 1h | ↑ / = | N/A | = |
| Husby (2010, Norway) | IG: 12; CG: 12 | IG: 58 ± 5; CG: 56 ± 8 | 15 (63) | Strengthening (+ control intervention) | I; L (Y) | 4w (5x pw) | 4 series of 5RM | 1w; 12m | Usual care | 5x pw | 1h | ↑ / = | N/A | = |
| Mikkelsen (2012, Denmark) | IG: 23; CG: 21 | 67.3 ± 7 | 16 (36) | Strengthening | O; L (N) | 12w (7x pw, 2x day) | 1x10 reps | 1d; 12w | Usual care | 7x pw, 2x day | 1x10 reps | = | = | = |
| Mikkelsen (2014, Denmark) | IG: 32; CG: 30 | IG: 64.8 ± 8; CG: 65.1 ± 10 | 26 (42) | Strengthening | O; L (P) | 10w (2x pw; 5x pw home-based exercise) | 30–40 min | <1w; 10w-12m | Usual care | 7x pw, 2x day | 1x10 reps | = | ↑ / = | = |
| Nankaku (2016, Japan) | IG: 14; CG: 14 | IG: 60.5 ± 6.4; CG: 60.8 ± 7.5 | 24 (86) | Strengthening (+ control intervention) | I; L (Y) | 4w (5x pw) | 3x8-12 reps | NR; 4w | Usual care | NR | NR | ↑ / = | ↑ | ↑ |
| Okoro (2016, UK) | IG: 25; CG: 24 | IG: 65.2 ± 9.1; CG: 66.3 ± 11.0 | 25 (51) | Strengthening | O; L (P) | 6w (5x pw) | Range of reps | 4-7d; 9-12m | Usual care | NR | NR | = | = / ↓ | N/A |
| Suetta (2004, Denmark) | IG: 13; CG: 12 | IG: 69 (range: 60–86); CG: 68 (range: 62–78) | 19 (53) | Strengthening (+ control intervention) | O; L (Y) | 12w (3x pw) | Progressively increased from 20RM to 8RM | ±7d; 12w | Usual care | 7x pw, 2x day | 1h | ↑ | ↑ / = | N/A |
| Maire (2004, France) | IG: 7; CG: 7 | 75.1 ± 4.8 | 12 (86) | Aerobic (+ control intervention) | I; L (NR) | 6w (3x pw) | 30 min | 1w; 2m | Usual care | 7x pw | 2h | N/A | N/A | = |
| Maire (2006, France) | IG: 7; CG: 7 | 75.1 ± 4.8 | 12 (86) | Aerobic (+ control intervention) | I; L (NR) | 6w (3x pw) | 30 min | 1w; 12m | Usual care | 7x pw | 2h | N/A | N/A | ↑ |
| Beaupre (2014, Canada) | IG: 11; CG: 10 | 53.4 ± 9.3 | 10 (48) | Functional | O; L/W (NR) | 3m (2x pw) | 2.5h | 6w; 12m | Usual care | NR | NR | = | = | = |
| Galea (2008, Australia) | IG: 11; CG: 12 | IG: 68.6 ± 9.7; CG: 66.6 ± 7.9 | 16 (70) | Functional | I; L (Y) | 8w (2x pw) | 45 min | 8w; 16w | Unsupervised home-based exercise | NR | NR | N/A | = | = |
| Giaquinto (2010, Italy) | IG: 31; CG: 39 | IG: 70.1 ± 8.5; CG: 70.6 ± 8.4 | IG: 21 (68); CG: 26 (67) | Functional | I; W (NR) | 3w (6x pw) | 40 min | <10d; 6m | Land-based therapy | 6x pw | 40 min | N/A | N/A | ↑ |
| Heiberg (2012, Norway) | IG: 35; CG: 33 | 66 (95% CI: 64, 67) | 35 (51) | Functional | O; L (Y) | 6w (2x pw) | 70 min | 3m; 12m | No supervised physiotherapy | NR | NR | = | ↑ / = | = |
| Heiberg (2016, Norway) | IG: 30; CG: 30 | 70 (95% CI: 68, 72) | 34 (57) | Functional | O; L (Y) | 6w (2x pw) | 70 min | 3m; 5y | No supervised physiotherapy | NR | NR | = | = | = |
| Johnsson (1988, Sweden) | IG: 14; CG: 16 | IG: 70 (range: 58–67); CG: 66 (range: 50–74) | 13 (43) | Functional | O; L (NR) | 2-3m (0,5-2x pw) | 45 min | 2m; 6m | No organized physiotherapy | NR | NR | = | = | = |
| Monaghan (2016, Ireland) | IG: 32; CG: 31 | IG: 68 ± 8; CG: 69 ± 9 | 20 (32) | Functional (+ control intervention) | O; L (Y) | 6w (2x pw) | 35 min | 12w; 18w | Usual care | NR | NR | = | ↑ | ↑/ = |
| Umpierres (2014, Brazil) | IG: 54; CG: 52 | 61.4 ± 15.0 | 57 (54) | Functional | I/O; L (P) | 2w (NR) | NR | 1d; 15d | No supervised physiotherapy | NR | NR | ↑ / = | N/A | = |
| Bodén (2004, Sweden) | IG: 10; CG: 10 | IG: 54 (range: 44–59); CG: 55 (range: 44–63) | 11 (55) | Functional and early full weight-bearing | O; L (N) | NR | NR | NR; 24m | Partial weight-bearing and home-based exercise | NR | NR | N/A | N/A | = |
| Monticone (2014, Italy) | IG: 50; CG: 50 | 69 ± 8 | 60 (60) | Functional and early full weight-bearing | I; L (Y) | 3w (5x pw) | 90 min | 4-7d; 12m | Partial weight-bearing and center-based exercise | 5x pw | 90 min | N/A | N/A | ↑ |
| Ström (2006, Sweden) | IG: 17; CG: 19 | 54.4 (range: 26–63) | 19 (53) | Functional and early full weight-bearing | O; L/W (Y) | 3m (NR) | NR | NR; 12m | Partial weight-bearing and a self-training program | NR | NR | = | N/A | N/A |
CG: control group; CI: confidence interval; IG: intervention group; NR: not reported.
a Age is shown as mean +/- SD, unless stated otherwise.
b Intervention: inpatient (I) or outpatient (O); land-based (L) or water-based (W).
c Whether the intervention was supervised: yes (Y), no (N) or partially (P).
d Shown as time since total hip arthroplasty: days (d), weeks (w), months (m) or years (y); pw: per week.
e Minutes (min); hours (h); repetition maximum (RM); repetitions (reps).
f Effect of the intervention: ↑ significant difference in favor of IG; = no significant difference between IG and CG; ↓ significant difference in favor of CG; N/A: not applicable as the article did not include this category of outcome measures.
g In this study a second intervention group was included that received neuromuscular electrical stimulation (NMES) in addition to the standard rehabilitation program (n = 11). However, the characteristics and results of this intervention group are not presented, since NMES was defined as an exclusion criterion for this systematic review.
Results of the therapeutic validity assessment using the CONTENT scale.
| Study | Patient eligibility | Setting & | Rationale | Content | Adherence | Total score | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Described | Adequate | Study | Intervention | Intensity | Monitored | Personalized | ||||
| Husby (2009) | No | No | Yes | Yes | Yes | Yes | Yes | No | No | 5 |
| Husby (2010) | No | No | Yes | Yes | Yes | Yes | Yes | No | No | 5 |
| Mikkelsen (2012) | No | No | No | Yes | Yes | Yes | No | Yes | Yes | 5 |
| Mikkelsen (2014) | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | 7 |
| Nankaku (2016) | No | No | Yes | No | No | No | No | No | Yes | 2 |
| Okoro (2016) | Yes | No | Yes | No | No | No | Yes | No | Yes | 4 |
| Suetta (2004) | No | No | Yes | No | No | No | Yes | No | No | 2 |
| Maire (2004) | No | No | No | No | No | No | Yes | Yes | No | 2 |
| Maire (2006) | No | No | No | Yes | Yes | Yes | Yes | No | No | 4 |
| Beaupre (2014) | No | No | No | No | No | No | No | No | No | 0 |
| Galea (2008) | No | No | No | Yes | No | No | No | No | Yes | 2 |
| Giaquinto (2010) | No | No | No | No | No | No | No | No | No | 0 |
| Heiberg (2012) | No | No | No | No | No | No | Yes | Yes | No | 2 |
| Heiberg (2016) | No | No | No | No | No | No | Yes | No | No | 1 |
| Johnsson (1988) | No | No | No | No | No | No | No | No | No | 0 |
| Monaghan (2016) | No | No | Yes | No | Yes | No | Yes | No | Yes | 4 |
| Umpierres (2014) | No | No | Yes | Yes | No | No | No | No | No | 2 |
| Bodén (2004) | No | No | No | No | No | No | No | No | No | 0 |
| Monticone (2014) | No | Yes | No | Yes | No | No | No | No | No | 2 |
| Ström (2006) | No | No | No | No | No | No | No | No | No | 0 |
| Total score | 2 (10%) | 2 (10%) | 8 (40%) | 8 (40%) | 5 (25%) | 5 (25%) | 10 (50%) | 3 (15%) | 6 (30%) | |
Overview of the total scores for therapeutic validity and risk of bias.
| Study | Therapeutic validity | Risk of bias | |
|---|---|---|---|
| CONTENT scale | PEDro scale | Cochrane Collaboration’s Tool | |
| Husby (2009) | 5 (56%) | 5 (50%) | No |
| Husby (2010) | 5 (56%) | 4 (40%) | No |
| Mikkelsen (2012) | 5 (56%) | No | |
| Mikkelsen (2014) | 5 (50%) | ||
| Nankaku (2016) | 2 (22%) | 4 (40%) | No |
| Okoro (2016) | 4 (44%) | No | |
| Suetta (2004) | 2 (22%) | 4 (40%) | No |
| Maire (2004) | 2 (22%) | 4 (40%) | No |
| Maire (2006) | 4 (44%) | 4 (40%) | No |
| Beaupre (2014) | 0 (0%) | ||
| Galea (2008) | 2 (22%) | 4 (40%) | No |
| Giaquinto (2010) | 0 (0%) | 3 (30%) | No |
| Heiberg (2012) | 2 (22%) | No | |
| Heiberg (2016) | 1 (11%) | No | |
| Johnsson (1988) | 0 (0%) | 3 (30%) | No |
| Monaghan (2016) | 4 (44%) | No | |
| Umpierres (2014) | 2 (22%) | No | |
| Bodén (2004) | 0 (0%) | No | |
| Monticone (2014) | 2 (22%) | No | |
| Ström (2006) | 0 (0%) | 5 (50%) | No |
Bold items indicate that the study is considered to be of adequate quality according to the assessment tool used.
a Data are shown as total score (percentage of the maximal possible score).
b Final judgment regarding adequate quality: yes (in case of low risk of bias for the items random sequence generation, allocation concealment and blinding of outcome assessment) or no.